Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Kamada

KMDA
Current price
6.69 USD +0.07 USD (+1.06%)
Last closed 6.58 USD
ISIN IL0010941198
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 380 683 104 USD
Yield for 12 month +26.70 %
1Y
3Y
5Y
10Y
15Y
KMDA
21.11.2021 - 28.11.2021

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. Address: 2 Holzman Street, Rehovot, Israel, 7670402

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

14.40 USD

P/E ratio

26.48

Dividend Yield

3.00 %

Current Year

+160 953 000 USD

Last Year

+142 519 000 USD

Current Quarter

+39 005 000 USD

Last Quarter

+41 740 000 USD

Current Year

+69 967 000 USD

Last Year

+55 490 000 USD

Current Quarter

+17 031 000 USD

Last Quarter

+17 234 000 USD

Key Figures KMDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 32 367 000 USD
Operating Margin TTM 13.02 %
Price to Earnings 26.48
Return On Assets TTM 3.45 %
PEG Ratio 0.95
Return On Equity TTM 5.75 %
Wall Street Target Price 14.40 USD
Revenue TTM 160 952 992 USD
Book Value 4.51 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 7.10 %
Dividend Yield 3.00 %
Gross Profit TTM 69 967 000 USD
Earnings per share 0.25 USD
Diluted Eps TTM 0.25 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY -18.60 %
Profit Margin 8.98 %

Dividend Analytics KMDA

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History KMDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date 17.03.2025
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years 0
Consistent Years 0
Continuous Dividends 0
Forward Annual Dividend Yield 3.00 %
Forward Annual Dividend – USD
Last Split Factor
Payout Ratio TTM 76.92 %
Last Split Date

Stock Valuation KMDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 26.48
Forward PE 23.81
Enterprise Value Revenue 1.90
Price Sales TTM 2.37
Enterprise Value EBITDA 10.99
Price Book MRQ 1.46

Financials KMDA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators KMDA

For 52 weeks

4.61 USD 8.90 USD
50 Day MA 6.85 USD
Shares Short Prior Month 56 788
200 Day MA 6.15 USD
Short Ratio 0.24
Shares Short 34 151
Short Percent 0.11 %